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Abstract This study aimed to use a population-based
Prescription Database to explore later development of dia-
betes in women registered with gestational diabetes mellitus
(GDM)and/orpreeclampsiaintheMedicalBirthRegistryof
Norway (MBRN) during 2004–8. We used two nationwide
Norwegian registries, the Norwegian Prescription Database
and the MBRN, to explore the onset of later diabetes after
pregnancy complications, indicated by receiving prescrip-
tions of drugs used to treat diabetes, in 230,000 women
giving birth in 2004–8. The mean follow-up of the study
cohort was 3.7 years. Five years after pregnancy, about 19
and 2% of women with GDM and preeclampsia, respec-
tively, received drugs used to treat diabetes, compared to
0.5%ofthosewithoutthesecomplications.Theriskofbeing
dispensed drugs used to treat diabetes within the ﬁrst years
after pregnancy was estimated to be 41 times (95% CI:
35–47) and 3.0 times (95% CI: 2.4–3.6) higher in women
with GDM and preeclampsia, respectively, compared to
women without these pregnancy complications. Women
with pregnancies complicated with preeclampsia or GDM
had an increased risk of later diabetes, especially those
having GDM. If the increase in frequencyof GDM observed
inMBRNinrecentyearsisreal,afurtherincreaseindiabetic
women can be expected.
Keywords Cohort  Diabetes mellitus  Drug
prescriptions  Population-based registries
Abbreviations
ATC Anatomical therapeutic chemical
CI Conﬁdence interval
GDM Gestational diabetes mellitus
ICD International Classiﬁcation of Diseases
MBRN Medical Birth Registry of Norway
NorPD Norwegian Prescription Database
PCOS Polycystic ovary syndrome
RR Relative risk
Introduction
Various forms of diabetes are a common and increasing
health problem in many parts of the world. Worldwide, the
number of adults above 20 years with diabetes has been
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DOI 10.1007/s10654-010-9527-4estimated to 171 million in year 2000 and 366 million in
2030 [1]. Deaths attributable to diabetes in year 2000 have
been estimated to 2.9 million worldwide [2].
Gestational diabetes mellitus (GDM) develops during
pregnancy and usually disappears thereafter [3, 4]. In the
US, GDM affects about 4% of pregnant women [5]. In
Norway, the incidence of GDM is relatively low. In 2008,
GDM appeared in about 1.3% of the pregnancies, being
about doubled during the last decade, according to statistics
from Medical Birth Registry of Norway (MBRN) [6].
Maternal diabetes type 1 and 2 appeared in 0.4 and 0.3% of
the pregnancies in 2008, respectively.
Several studies have linked GDM to increased risk of
later diabetes [7–10], especially type 2 diabetes. Another
disorder during pregnancy, preeclampsia, has been linked
to GDM [11, 12] and also to later diabetes [13, 14]. Pre-
eclampsia is, in Norway, much more common than GDM;
preeclampsia was reported in about 3.6% of the pregnan-
cies in 2008 [6].
The establishment of the Norwegian Prescription Data-
base (NorPD) in 2004 made it possible to link data on
maternal diseases during pregnancy from the MBRN with
the maternal use of medication [15]. This study aimed to
use the population-based NorPD to explore later develop-
ment of diabetes in women registered with GDM and/or
preeclampsia in MBRN during 2004–8.
Materials and methods
Data sources
Norwegian prescription database [16] is a research data-
base which captures all dispensed prescriptions in Norway
from January 1st, 2004, and covers the entire population of
Norway (4.9 million). NorPD contains information on all
prescribed drugs, reimbursed or not, dispensed at phar-
macies to individual patients treated in ambulatory care.
Data on use in institutionalized patients in nursing homes
and hospitals are also collected, but these ﬁgures are only
registered at an institutional and not at the individual level.
Therefore, drugs dispensed to institutions are not included
in our study. For each prescription, the sex and age of the
patient, demographic information, dispensing date, and
detailed drug information are registered. Until March 2009,
the indication for prescribing was not recorded. Classiﬁ-
cation of drugs is based on the Anatomical Therapeutic
Chemical (ATC) classiﬁcation system [17].
Medical Birth Registry of Norway is a population
based registry containing information on all births in
Norway since 1967 (nearly 2.5 million births) [18].
MBRN is based on compulsory notiﬁcation of every
birth or late abortion from 12 completed weeks of
gestation onwards, and includes identiﬁcation on the
parents by their personal identity numbers, demographic
information of the parents, the mother’s diseases before
and during pregnancy, complications during pregnancy
and delivery, length of pregnancy as well as information
on the infant, including birth defects and other perinatal
problems [18].
Maternal diseases, before and during pregnancy are
coded by the staff at the MBRN using International Clas-
siﬁcation of Diseases (ICD) revision 10. In this study, we
used variables for preeclampsia and GDM as deﬁned by
MBRN. The coding of GDM and diabetes in general in
MBRN is described by Stene et al. [19]. The diagnostic
criteria for preeclampsia in Norway have been blood
pressure C 140/90 after 20 weeks of gestation, combined
with proteinuria C0.3 g/24 h) (C?1 dipsticks) on at least
two occasions [20]. From 1999 onwards, a variable indi-
cating whether preeclampsia was diagnosed before week
34 of gestation and a variable indicating whether the pre-
eclampsia was mild or severe have been included in
MBRN. In this study, these two variables were combined,
preeclampsia diagnosed before week 34 was regarded as
severe.
Study subjects
Data in MBRN, including eventual date of death/emigra-
tion for mother and child, were linked to NorPD using the
unique 11-digit identiﬁcation number, assigned to all
individuals living in Norway after 1960. In our study,
women with pregnancies (excluding abortions) registered
in MBRN during 2004–8, lasting more than 22 weeks were
included (n = 231,668 pregnancies when counting each
women’s ﬁrst pregnancy in the period). Only each
woman’s ﬁrst pregnancy in the study period was included
in our study. After exclusion of women with diabetes,
polycystic ovary syndrome (PCOS) or chronic hyperten-
sion before pregnancy according to MBRN, the remaining
number of women was 228,116. According to NorPD,
1,126 women (i.e. 0.5% of the pregnant women) received
drugs used to treat diabetes (ATC code A10) prior to
pregnancy (possible pre-existing diabetes mellitus). In
addition, among women not having GDM, 47 women used
insulin during pregnancy according to MBRN and 111
women not having registered GDM received drugs used to
treat diabetes during pregnancy according to NorPD. After
excluding all these women, 226,832 women remained
(Fig. 1).
These women were followed with regard to prescrip-
tions from the latest of January 1, 2004 and the date of
giving birth, until prescription of the drugs in question,
emigration or death or December 31, 2009, whichever
occurred ﬁrst.
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123Methods
Prescriptions of drugs used to treat diabetes (ATC code
A10) were used as proxy for diabetes. Prescriptions were
divided into insulin (A10A: fast-acting, intermediate act-
ing, intermediate-acting combined with fast-acting, long-
acting [17]) and oral antidiabetics (A10B: biquanides,
sulfonamides, alpha glucosidase inhibitors, thiazolidinedi-
ones, meglitinides [17]). Those receiving drugs used to
treat diabetes were divided into three groups; those
receiving insulin only, those receiving oral antidiabetics
only and those receiving both insulin and oral antidiabetics.
Prescriptions during subsequent pregnancies were
excluded.
The time from giving birth to the date of receiving drugs
or the censoring date was analysed with the use of the
Kaplan–Meier method and Cox proportional hazards
models, with adjustment for maternal age, tested as cate-
gorical (\20, 20–29, 30–39 and C 40 years) but included
as continuous, and for parity (ﬁrst pregnancy, second
pregnancy, third pregnancy or more).
Hazard ratios, in this paper denoted relative risks (RRs),
of receiving dispensed drugs used to treat diabetes were
estimated in multivariate Cox proportional hazards models.
Using maternal age as continuous variable in the models
gave similar results. Since women with GDM may be
screened for diabetes at some time postpartum, analyses
were also performed excluding the ﬁrst 6 months after
giving birth.
The analysis were repeated using prescription of insulin
(ATC code A10A) and oral antidiabetics (A10B), respec-
tively, instead of the whole group of drugs used to treat
diabetes (A10).
Data handling and analyses were performed using Stata
and SPSS [21, 22].
Results
Altogether, 2,198 (1.0%) of the included pregnancies were
complicated with GDM and 8,832 (3.9%) with pre-
eclampsia, according to MBRN (Table 1). In pregnancies
with GDM (mean maternal age 32 years), the mothers were
older than in pregnancies without GDM (mean maternal
age 30 years). Among mothers with GDM, 176 (8.0%) had
preeclampsia as well. After a mean follow-up of 3.7 years
(range: 0–6 years after birth), 1,193 (0.5%) of all mothers
received prescriptions of drugs used to treat diabetes (ATC:
A10); 0.4 and 14% of those without and with GDM and 0.5
and 1.6% of those without and with preeclampsia,
respectively. Among those receiving drugs, 83% received
biguanides (A10BA), 21% received intermediate-acting
(A10AC) and 20% received fast-acting insulins and ana-
logues for injection (A10AB). Overall, about 0.5% of
women without GDM and preeclampsia received a pre-
scription of drugs used to treat diabetes during the ﬁrst
5 years after giving birth.
Overall, about 19% of the mothers with GDM without
preeclampsia received a prescription of drugs used to treat
diabetes (insulin and/or oral antidiabetics) during the ﬁrst
5 years after giving birth (Fig. 2). The number of women
included in the calculations of frequency of receiving an-
tidiabetics is shown in Table 2. These women had about 41
times higher risk of receiving drugs used to treat diabetes
than those without GDM or preeclampsia (Table 3). About
2% of the mothers with preeclampsia without GDM
received a prescription of drugs used to treat diabetes
(insulin and/or oral antidiabetics) during the ﬁrst 5 years
after giving birth. These women had 3.0 times higher risk
of receiving drugs used to treat diabetes than those without
GDM or preeclampsia. Women with severe preeclampsia
(33% of the preeclamptic pregnancies) had a higher risk of
receiving prescription of drugs used to treat diabetes than
other women with preeclampsia (RR 1.6, 95% CI 1.2–2.1).
Analyses excluding the ﬁrst 6 months after giving birth,
gave similar results.
We also studied the risks of receiving insulin or oral
antidiabetics separately:
Compared with those receiving drugs used to treat dia-
betes in general, the group receiving insulin only had a
231,668
Eligible women registered with a birth in MBRN 2004-8 
1775 women had diabetes, 720 
women had PCOS*, 1057 
women had chronic 
hypertension prior to pregnancy 
according to MBRN, and were 
excluded
226,832
Study population
1126 received antidiabetics 
(NorPD) prior to pregnancy,
111 received antidiabetics 
(NorPD), and 47 received 
insulin (MBRN) during 
pregnancy without having GDM 
Fig. 1 Flow chart of the study population. Births registered in the
Medical Birth Registry of Norway (MBRN) 2004–8 linked to the
nationwide Norwegian Prescription Database (NorPD) 2004–9.
*PCOS- Polycystic ovary syndrome
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123higher RR connected to having GDM (Table 2). The group
receiving oral antidiabetics only, had a lower relative risk
connected to GDM.
Overall, 10% of the women with GDM without pre-
eclampsia received a prescription of insulin during the ﬁrst
5 years after giving birth (data not shown). These women
had 129 times (95% CI 102–163) higher risk of receiving
insulin than those without GDM or preeclampsia. Less than
1% of the mothers with preeclampsia without GDM
received a prescription of insulin during the ﬁrst 5 years
after giving birth. These women had 2.9 times (95% CI
1.7–4.7) higher risk of receiving insulin during the follow-
up time than those without GDM or preeclampsia.
Overall, 13% of the mothers with GDM without pre-
eclampsia received a prescription of oral antidiabetics
during the ﬁrst 5 years after giving birth (data not shown).
These women had about 28 times (95% CI 24–34) higher
risk of receiving oral antidiabetics than those without GDM
or preeclampsia. About 2% of the mothers with pre-
eclampsia without GDM received a prescription of oral
antidiabetics during the ﬁrst 5 years after giving birth.
These women had 3.0 times (95% CI 2.4–3.8) higher risk
of receiving oral antidiabetics than those without GDM or
preeclampsia.
Discussion
This study included almost 230,000 pregnant women giv-
ing birth during 2004–8. Nearly 2,200 women developed
GDM. After a mean follow-up of 3.7 years, almost 1,200
women were dispensed drugs used to treat diabetes (insulin
and/or oral antidiabetics). The probability of being dis-
pensed drugs used to treat diabetes was estimated to be 41
Table 1 Characteristics of the
study population
Data from pregnancies in
2004–8 (n = 226,832), Medical
Birth Registry of Norway
(MBRN) and from the
Norwegian Prescription
Database (NorPD)
GDM Gestational diabetes
mellitus
Pregnancies without GDM Pregnancies with GDM
Total no. of
women
% Total no. of
women
%
Year of childbirth
2004 54,659 24.3 472 24.3
2005 52,096 23.2 433 23.2
2006 45,259 20.1 478 20.2
2007 37,651 16.8 388 16.8
2008 34,969 15.6 427 15.6
Maternal age (years)
\20 6,063 2.7 21 1.0
20–29 105,675 47.0 750 34.1
30–39 106,921 47.6 1,264 57.5
40? 5,975 2.7 163 7.4
Length of pregnancy (weeks)
22–24 351 0.2 1 0.0
25–36 13,902 6.2 238 10.8
37–39 89,555 39.9 1,198 54.4
40–41 103,994 46.3 712 32.4
42? 16,832 7.5 52 2.4
Preeclampsia
No 215,988 96.2 2,022 92.0
Yes 8,646 3.8 176 8.0
Condition
Stillbirth 890 0.4 4 0.2
Livebirth 223,744 99.6 2,194 99.8
Medication after pregnancy (2004–9)
Drugs used to treat diabetes (A10) 891 0.4 302 13.7
Of these
Only insulin (A10A) 122 13.1 106 34.4
Only oral antidiabetics (A10B) 772 82.9 144 46.8
Both insulin and oral antidiabetics 37 4.0 58 18.8
Total 224,634 100 2,198 100
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123times and 3 times higher in women with GDM and pre-
eclampsia, respectively, compared to women without these
pregnancy complications.
The major strength of our study was the use of two
nationwide registries, the MBRN and the NorPD, and the
unique 11-digit personal identity number, which ensured
valid data linkage between the two registries. Other
advantages were the large sample size, a prospective design
and that the NorPD includes prescriptions from all prac-
ticing physicians prescribing to patients living outside
institutions in Norway, both general practitioners and
specialists. Further, the study covered all births in the
Norwegian population (about 4.9 million).
Recently, the diabetic diagnoses in MBRN have been
compared with NorPD [23]. The sensitivity, i.e. the pro-
portion of women indicated to be diabetic in NorPD that
was registered as diabetic in MBRN, was found to be 72%.
In our study, 1,775 mothers were excluded due to previous
diagnoses of diabetes. Assuming a sensitivity of 72%,
another 700 mothers should have been excluded. Based on
information from NorPD, we excluded additionally 1,126
women that received antidiabetics prior to pregnancy. In
the previous study 3% of those with GDM received drugs
used to treat diabetes during the 3 months prior to preg-
nancy. Even if 3% of mothers registered with GDM was
diabetic before pregnancy, and hence did not have GDM,
0
.
0
0
0
.
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0
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5
0
0
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7
5
1
.
0
0
0 1 2 3 4 5
Time since giving birth
gr = No preeclampsia nor GDM gr = Preeclampsia, without GDM
gr = GDM, without preeclampsia gr = Preeclampsia and GDM
Fig. 2 Kaplan-Meier graph of estimated overall proportion of
mothers receiving drugs used to treat diabetes (ATC-code A10) by
time since giving birth, by disease status (GDM and/or preeclampsia).
The estimates are based on data from women giving birth 2004–8
(n = 226,832)
Table 2 Number of women without previously received prescriptions of antidiabetics by years since giving birth
Years since giving birth
012345
Group
No preeclampsia nor GDM 215,988 215,202 181,318 145,095 101,771 51,995
Preeclampsia (without GDM) 8,646 8,615 7,163 5,630 3,874 1,919
GDM (without preeclampsia) 2,022 2,012 1,615 1,258 831 433
Preeclampsia and GDM 176 175 138 109 67 34
Total 226,832 226,004 190,234 152,092 106,543 54,381
GDM Gestational diabetes mellitus
Table 3 Relative risk of getting dispensed drugs used to treat diabetes (insulin and/or oral antidiabetics), with 95% conﬁdence intervals (95%
CI), obtained in Cox regression analysis, adjusted for maternal age and parity
% Drugs used to treat
diabetes
Both insulin and oral
antidiabetics*
Oral antidiabetics only Insulin only
Relative risk 95% CI Relative risk 95% CI Relative risk 95% CI Relative risk 95% CI
Group
No preeclampsia nor GDM 95.2 1.0 Referent 1.0 Referent 1.0 Referent 1.0 Referent
Preeclampsia (without GDM) 3.8 3.0 2.4–3.6 4.2 1.6–11 3.0 2.4–3.7 2.5 1.4–4.5
GDM (without preeclampsia) 0.9 41 35–47 184 117–290 22 18–27 118 90–156
Preeclampsia and GDM 0.1 79 58–108 430 204–905 52 34–79 145 76–278
Data from pregnancies in 2,004–8 (n = 226,832)
GDM Gestational diabetes mellitus
* Excluding those receiving insulin only or oral antidiabetics only
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123the proportion of women with GDM receiving drugs used
to treat diabetes after giving birth, was very high.
Some doctors may prescribe insulin to breastfeeding
women in order to control their blood glucose levels and
reduce potential harm to the infants. We repeated the
analyses excluding the ﬁrst 6 months after giving birth.
This exclusion had little impact on the results.
Other studies have documented the association between
GDM and subsequent diabetes, but this is, to our knowl-
edge, the largest and most comprehensive study.
Another study [19] found a positive predictive value of
GDM in the MBRN, i.e. the proportion of women regis-
tered with GDM in MBRN having GDM, of 89% for births
in 1998. However, GDM may be underreported in MBRN,
and only the most serious cases of GDM may have been
registered. If so, mothers with less severe GDM have been
included in the reference group in our study. The group of
mothers with GDM in this study will then, however,
probably consist of women with severe GDM.
We had no information on the weight of the mothers,
neither before, during nor after pregnancy. Obesity is one
of the main risk factors for diabetes type 2. It is also
associated with both preeclampsia and GDM. Hence, in a
population with higher BMI, the association between
GDM/preeclampsia and subsequent diabetes probably
would have been stronger than observed here. Other
potential confounders are family history of DM, socio-
economic status (SES), ethnicity, parity, folic acid use
during pregnancy, smoking and twinning. We made
adjustments for the parity of the mothers in the analyses.
Rough smoking habits at the beginning and end of preg-
nancy was available for 79% of the women. In women not
smoking neither at the beginning nor end of pregnancy, the
results was about the same as for the entire study popula-
tion. Use of folic acid during pregnancy is recorded in
MBRN (yes/no); about 51% of the women used folic acid.
Including this information in the analysis, did not change
the results. The issue of twinning is complex and needs
speciﬁc attention. However, in this study we chose to
restrict the included pregnancies to those resulting in single
births. The severity of GDM and when GDM was mani-
fested was not recorded. Severity and timing of GDM may
be related to the risk of getting diabetes later.
Disease codes were not included in NorPD before
March 2009, so we could only exclude women having
hypertension prior to pregnancy according to MBRN.
About 1% of the women included, used medications pre-
scribed to treat hypertension (among other conditions)
prior to pregnancy. Excluding these women resulted in
only small changes in the results.
Some women had more than one pregnancy during the
study period. We chose to include only the ﬁrst pregnancy
for each woman in the study period. By doing this, we
avoided to include the same event (being prescribed and
dispensed antidiabetic drugs) several times and avoided
dependencies within the data set.
Some diabetic women do not use drugs for diabetes. In
the US, overall 16% of adults with diagnosed diabetes
(type 1 or type 2), did not take insulin nor oral medication
[5]. In our study, the indicated proportion of mothers
developing diabetes after pregnancy may be underesti-
mated. However, our results would be inﬂuenced only if
the proportion of diabetics not receiving drugs differed
according to whether they had GDM and/or preeclampsia.
Most studies on later risk of diabetes in mothers after
pregnancies complicated with preeclampsia or GDM focus
on the risk of type 2 diabetes [7–10]. In our study we could
not separate the two main types of diabetes in data from
NorPD. However, since women with type 1 diabetes before
pregnancy were excluded, and this type of diabetes usually
is diagnosed during childhood and adolescence, most of the
women receiving antidiabetic drugs in our study probably
had type 2 diabetes.
In a Norwegian hospital-based clinical study of women
with GDM [24], 60% developed diabetes within 16 years.
In a Canadian cohort study, 19% of women with GDM
developed diabetes during the ﬁrst 9 years [7]. According
to Kjos and Buchanan, women with GDM have 17–63%
risk of nongestational diabetes within 5 to 16 years after
pregnancy [25]. We estimated that in women having GDM,
but not preeclampsia, 19% received drugs used to treat
diabetes within 5 years after giving birth. In a Danish
cohort study, Lykke et al. [14] found a threefold increased
risk of diabetes type 2 after a mean follow-up of 15 years
in women with preeclampsia. After a mean follow-up of
3.7 years, we found a threefold increased risk of receiving
drugs used to treat diabetes.
In women without GDM and preeclampsia, the fre-
quency of using drugs used to treat diabetes 5 years after
giving birth was low. Women having pregnancies com-
plicated with preeclampsia or GDM had an increased risk
of later diabetes. The relative risk was high in women
having GDM (and highest in women with both GDM and
preeclampsia). A high proportion of mothers with GDM
will need drugs to treat diabetes within 5 years after
pregnancy. If the increase of GDM registered in MBRN in
recent years is real, a further increase in diabetic women
can be expected. Women with GDM should be a target
group for interventions aimed at preventing type 2 diabetes.
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